Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Key Points

• Short interest in Theratechnologies Inc. saw a significant decline of 30.2% in August, totaling 209,400 shares as of August 31, down from 300,200 shares mid-month.
• The company's quarterly earnings reported a loss of ($0.09) EPS, missing analysts' expectations, with revenues of $17.73 million, below the anticipated $24.30 million.
• Hedge fund activity includes a striking 1,416.7% increase in holdings by Bank of America during the 4th quarter, along with new investments from various firms totaling approximately $39,000 to $41,000 each.

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 209,400 shares, a decline of 30.2% from the August 15th total of 300,200 shares. Based on an average daily volume of 525,200 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the company's stock are short sold. Approximately 0.6% of the company's stock are short sold. Based on an average daily volume of 525,200 shares, the short-interest ratio is currently 0.4 days.

Theratechnologies Price Performance

NASDAQ:THTX opened at $3.29 on Tuesday. The stock has a market cap of $151.27 million, a P/E ratio of -17.32 and a beta of 0.51. Theratechnologies has a one year low of $1.12 and a one year high of $3.31. The company has a fifty day moving average price of $3.20 and a 200 day moving average price of $2.59.

Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The business had revenue of $17.73 million for the quarter, compared to analysts' expectations of $24.30 million. As a group, equities research analysts anticipate that Theratechnologies will post 0.01 EPS for the current year.

Institutional Trading of Theratechnologies

A number of hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock worth $30,000 after buying an additional 15,400 shares during the period. Stonepine Capital Management LLC acquired a new stake in Theratechnologies during the 1st quarter worth approximately $36,000. BNP Paribas Financial Markets acquired a new stake in Theratechnologies during the 4th quarter worth approximately $36,000. Acadian Asset Management LLC acquired a new stake in Theratechnologies during the 1st quarter worth approximately $39,000. Finally, TD Waterhouse Canada Inc. raised its holdings in Theratechnologies by 63.4% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 18,038 shares of the company's stock worth $41,000 after buying an additional 7,000 shares during the period.

Analyst Ratings Changes

Separately, Jones Trading cut shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Theratechnologies presently has an average rating of "Buy".

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.